Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The study is an adaptive, phase 2, multicenter, three-part study to establish the dosage,
safety and antiviral activity of combination therapy with albuvirtide (ABT) and 3BNC117 as
long-acting maintenance therapy in virologically suppressed subjects with HIV-1 infection.